The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
XOMA Shares Down 17.9% Since SmarTrend's Sell Call (XOMA)
Comtex SmarTrend(R) - Tue Apr 01, 9:46AM CDT
SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 4 weeks, XOMA has returned 17.93% as of today's recent price of $5.54.
XOMA Down 17.5% Since SmarTrend Downtrend Call (XOMA)
Comtex SmarTrend(R) - Tue Mar 25, 9:23AM CDT
SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 3 weeks, XOMA has returned 17.48% as of today's recent price of $5.57.
Want Clinical Trial Success? Look Here
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 24, 5:30PM CDT
Companies can run into a variety of issues that trip up drugs that look good in early trials but fail later trials. From placebo effect, to small clinical trials, to uncontrolled trials, it can be hard for investors to gauge future successes on early...
Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
at The Street - Fri Mar 21, 10:00AM CDT
Stocks with insider trader activity include SFY, XOMA and SNI
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Why XOMA Corp. Shares Slumped
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 2:09PM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
Downgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Tue Mar 11, 7:58AM CDT
XOMA (NASDAQ:XOMA) was downgraded from Buy to Hold at MLV & Co. today. The stock closed yesterday at $6.43 on volume of 3.6 million shares, above average daily volume of 2.6 million. There is potential upside of 55.5% for shares of XOMA based on a current price of $6.43 and an average consensus analyst price target of $10.00. The stock should hit resistance at its 50-day moving average (MA) of $7.69, as well as support at its 200-day MA of $5.36.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Down 30%, Worth a Look
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 06, 8:32PM CST
It's never a good sign when the first paragraph of a press release announcing clinical trial results for one disease starts talking about the other trials where the drug is being tested. Investors didn't buy the smokescreen XOMA put up on...
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
PR Newswire - Thu Mar 06, 11:22AM CST
Editor Note: For more information about this release, please scroll to bottom.
XOMA (XOMA) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 06, 8:48AM CST
Trade-Ideas LLC identified XOMA (XOMA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Hovnanian Enterprises, XOMA, and Yongye International Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 05, 7:31PM CST
Having seen a big drop on Monday and a big jump on Tuesday, stocks took the Goldilocks route Wednesday, as the broader market finished little changed as investors struggled to guess which direction macroeconomic and geopolitical issues will push the...
After Yesterday's Decline of 27.75%, XOMA Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 05, 5:20PM CST
XOMA (NASDAQ:XOMA) traded in a range yesterday that spanned from a low of $6.80 to a high of $7.53. Yesterday, the shares fell 27.8%, which took the trading range below the 3-day low of $8.06 on volume of 17.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 05, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why XOMA Corp. Shares Zoomed Lower
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 12:57PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XOMA , a biopharmaceutical company...
Pipeline Setback Overshadows XOMA's Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:52AM CST
XOMA will not move gevokizumab into late-stage development for the EOA indication.